Next Article in Journal
Development, Characterization, and Evaluation of Chi-Tn mAb-Functionalized DOTAP-PLGA Hybrid Nanoparticles Loaded with Docetaxel for Lung Cancer Therapy
Previous Article in Journal
Bioactive Hydrogel Supplemented with Stromal Cell-Derived Extracellular Vesicles Enhance Wound Healing
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

Flavonoids as Potential Modulators of Pancreatic Lipase Catalytic Activity

1
Laboratório Associado para a Química Verde (LAQV), Rede de Química e Tecnologia (REQUIMTE), Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira nº 228, 4050-313 Porto, Portugal
2
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
3
Laboratório Associado para a Química Verde (LAQV), Rede de Química e Tecnologia (REQUIMTE), Department of Chemistry, University of Aveiro, 3800-193 Aveiro, Portugal
4
UCIBIO—Applied Molecular Biosciences Unit, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
5
Associate Laboratory i4HB—Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2025, 17(2), 163; https://doi.org/10.3390/pharmaceutics17020163
Submission received: 18 November 2024 / Revised: 9 January 2025 / Accepted: 21 January 2025 / Published: 25 January 2025
(This article belongs to the Section Drug Targeting and Design)

Abstract

Background/Objectives: Obesity has reached pandemic proportions, with predictions suggesting that, by 2030, over 1.5 billion people will be affected. Pancreatic lipase (PL), the enzyme primarily responsible for the absorption of dietary lipids, presents a potential target for obesity management. However, while porcine pancreatic lipase (PPL) is commonly used as the enzyme source for screening potential inhibitors, its effect on human pancreatic lipase (HPL) is rarely reported. This work aimed to screen the inhibitory effects of a library of flavonoids with different functional groups on the activity of PL from the human pancreas (triacylglycerol acyl hydrolase, EC 3.1.1.3) and compare it to the effects of the porcine pancreas (type II, EC 3.1.1.3), establishing, whenever possible, a structure–activity relationship. Methods: The inhibitory effects of a library of 48 flavonoids with different hydroxy, glycosyl, rutinosyl, galloyl, and extended alkyl groups were evaluated against PPL and HPL. The kinetic parameters and inhibitory mechanisms of the most active flavonoids were determined, and in silico docking studies of the more potent flavonoids were also performed, using the active site of HPL. Results/Conclusions: Variations in enzyme catalytic activity were observed depending on the source of the enzyme. The inhibitory effect was particularly influenced by the presence of extended alkyl groups at the C-3 of the C-ring and the C2=C3 double bond of the C-ring and the presence of a pyrogallol group at the C-2′, C-3′ and C-4′ of the B-ring. Docking results showed a strong correlation between docking scores and observed inhibitory activities, highlighting the critical role of specific substituents on the flavonoid backbone in enhancing detailed interaction dynamics with key amino acids. Compounds 28, 29, and 30, with alkyl groups, showed the highest docking scores, interacting with residues HIS151, PHE215, ARG256, and HIS263. Further analysis also revealed that specific substituents improved pocket occupancy and formed additional interactions with residues TYR114, PRO180, ILE209, and PHE215, which are crucial for inhibition. These binding characteristics closely mimic those observed with orlistat, reinforcing their mechanistic similarities in inhibiting HPL and validating their inhibitory activities.
Keywords: obesity; pancreatic lipase inhibition; in vitro; in silico; flavonoids; structure–activity relationship obesity; pancreatic lipase inhibition; in vitro; in silico; flavonoids; structure–activity relationship

Share and Cite

MDPI and ACS Style

Rocha, S.; Proença, C.; Araújo, A.N.; Freitas, M.; Rufino, I.; Aniceto, N.; Silva, A.M.S.; Carvalho, F.; Guedes, R.C.; Fernandes, E. Flavonoids as Potential Modulators of Pancreatic Lipase Catalytic Activity. Pharmaceutics 2025, 17, 163. https://doi.org/10.3390/pharmaceutics17020163

AMA Style

Rocha S, Proença C, Araújo AN, Freitas M, Rufino I, Aniceto N, Silva AMS, Carvalho F, Guedes RC, Fernandes E. Flavonoids as Potential Modulators of Pancreatic Lipase Catalytic Activity. Pharmaceutics. 2025; 17(2):163. https://doi.org/10.3390/pharmaceutics17020163

Chicago/Turabian Style

Rocha, Sílvia, Carina Proença, Alberto N. Araújo, Marisa Freitas, Ismael Rufino, Natália Aniceto, Artur M. S. Silva, Félix Carvalho, Rita C. Guedes, and Eduarda Fernandes. 2025. "Flavonoids as Potential Modulators of Pancreatic Lipase Catalytic Activity" Pharmaceutics 17, no. 2: 163. https://doi.org/10.3390/pharmaceutics17020163

APA Style

Rocha, S., Proença, C., Araújo, A. N., Freitas, M., Rufino, I., Aniceto, N., Silva, A. M. S., Carvalho, F., Guedes, R. C., & Fernandes, E. (2025). Flavonoids as Potential Modulators of Pancreatic Lipase Catalytic Activity. Pharmaceutics, 17(2), 163. https://doi.org/10.3390/pharmaceutics17020163

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop